Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen (born 29 November 1966) is a Danish businessman and was the chief executive of Novo Nordisk between January 2017 and August 2025. He is the chairman of the European Federation of Pharmaceutical Industries and Associations.

Early life and education Jørgensen was educated at the Cathedral School of Viborg. In 1991 Jørgensen earned an MSc in Finance & Business Administration from Aarhus University.

In September 2016, it was announced that Jørgensen would succeed Lars Rebien Sørensen as CEO of Novo Nordisk, after Sørensen had announced his departure at the end of the year. In January 2017, Jørgensen was appointed president and chief executive officer.

Senate hearing On 24 September 2024, Jørgensen appeared before the Senate Committee on Health Education, Labor, and Pensions to defend Ozempic and Wegovy drug pricing. The committee, led by Bernie Sanders, reiterated the point that drug prices should be substantially lowered. Jørgensen reiterated that pharmacy benefit managers, PBMs, lower coverage when prices have a lower list price, thus making the access to the drugs harder for individuals. Sanders claimed three of the top PBMs promised to not reduce access if prices are lowered, however, Jørgensen had his doubts to these claims. Roger Marshall, a physician, sided with Novo Nordisk and showed sympathy saying Novo Nordisk "is not a villain in this story, they're a hero."

Honours May 2019: Knight of the Order of the Dannebrog 2020: Lederne Leader of the Year December 2023: Financial Times Person of the Year